AU Patent

AU2006309013B2 — Bi-aryl meta-pyrimidine inhibitors of kinases

Assigned to Impact Biomedicines Inc · Expires 2012-06-28 · 14y expired

What this patent protects

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases.

USPTO Abstract

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases.

Drugs covered by this patent

Patent Metadata

Patent number
AU2006309013B2
Jurisdiction
AU
Classification
—
Expires
2012-06-28
Drug substance claim
No
Drug product claim
No
Assignee
Impact Biomedicines Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.